5α,17βH-pregn-20-yn-17-ol | 127995-39-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5α,17βH-pregn-20-yn-17-ol
• 英文别名: 5α,17βH-Pregn-20-in-17-ol；17α-ethynyl-5α-androstan-17β-ol；17α-Aethinyl-5α-androstanol-(17β)；17-Ethynyl-5alpha-androstan-17beta-ol；(5R,8R,9S,10S,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-ol
• CAS: 127995-39-5
• 化学式: C₂₁H₃₂O
• 分子量: 300.484
• InChiKey: DNZAUZMYWADSJC-OGNRNXDYSA-N

物化性质

• 沸点：
  392.1±11.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5α,17βH-pregn-20-yn-17-ol 在 Pd-BaSO₄ 、 乙酸乙酯 作用下， 生成 5α,17βH-pregnan-17-ol
  参考文献：
  名称：

  Steroids. XI.^1a 17-Ethynylandrostan-17β-ol and Androstane-2,17-dione^1b

  摘要：

  DOI：

  10.1021/ja01168a504
• 作为产物：
  描述：

  (5alpha)-雄甾烷-17-酮 在 potassium tert-butylate 、 甲苯 、 乙炔 作用下， 生成 5α,17βH-pregn-20-yn-17-ol
  参考文献：
  名称：

  Steroids. XI.^1a 17-Ethynylandrostan-17β-ol and Androstane-2,17-dione^1b

  摘要：

  DOI：

  10.1021/ja01168a504

文献信息

• [EN] PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE LA PROGESTÉRONE ET UTILISATIONS CORRESPONDANTES
  申请人：INST NAT SANTE RECH MED

  公开号：WO2011138460A1

  公开（公告）日：2011-11-10

  The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.

  本发明涉及一种化合物，其化学式为(I)，用作孕激素受体拮抗剂，特别是用于预防和/或治疗癌症或子宫病变。
• Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
  申请人：——

  公开号：US20040121991A1

  公开（公告）日：2004-06-24

  The present invention is related to acute therapeutic uses of dehydroepiandrosterone (DHEA) congeners. These uses include methods for treating or preventing ulcers which comprise administering to a subject either at risk or in need thereof having an ulcer a therapeutic amount of DHEA congener.

  本发明涉及脱氢表雄酮（DHEA）类似物的急性治疗用途。这些用途包括治疗或预防溃疡的方法，包括向患有溃疡风险或需要治疗的受试者施用治疗量的DHEA类似物。
• PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Rafestin-Oblin Marie-Edith

  公开号：US20130203718A1

  公开（公告）日：2013-08-08

  The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.

  本发明涉及一种化合物，其化学式为（I）：用作孕激素受体拮抗剂，特别是用于预防和/或治疗癌症或子宫病理学的用途。
• Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
  申请人：——

  公开号：US20040067920A1

  公开（公告）日：2004-04-08

  This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone, its analogue(s) or salt(s) by itself or with a pharmaceutically or veterinarily acceptable carrier or diluent, and having a particle size of about 0.1 &mgr;m to about 100 &mgr;m. The formulation can be used to treat or prevent asthma, chronic obstructive pulmonary disease, lung inflammation, and other respiratory diseases or conditions. The formulation may be prepared by jet milling, and may be delivered through the respiratory tract or other routes using a nebulizer. The sealed container is provided in a device and/or a therapeutic kit.

  本发明涉及一种装有粉末制剂的密封容器，该制剂本身或与药学上或兽医学上可接受的载体或稀释剂一起含有脱氢表雄酮、其类似物或盐，其粒度约为 0.1mgr;m 至约 100mgr;m。该制剂可用于治疗或预防哮喘、慢性阻塞性肺病、肺部炎症和其他呼吸道疾病或病症。制剂可通过喷射研磨制备，并可使用雾化器通过呼吸道或其他途径输送。密封容器装在设备和/或治疗包中。
• Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation
  申请人：Patel Dinesh

  公开号：US20060122160A1

  公开（公告）日：2006-06-08

  The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with a parthenolide to reduce inflammation.

  本发明涉及脱氢表雄酮（DHEA）同系物的治疗用途。更具体地说，本发明涉及将脱氢表雄酮（DHEA）同系物与一种非那雄胺联合施用以减轻炎症。